[PDF][PDF] FGFR1 expression correlates inversely with the efficacy of single-agent FGFR-specific inhibitors in pancreatic cancer
Pancreatic adenocarcinoma (PDAC) is projected to become the second leading cause of
cancer deaths by 2030, and its five-year survival is 12%(Rahib et al., 2014; Siegel, Miller …
cancer deaths by 2030, and its five-year survival is 12%(Rahib et al., 2014; Siegel, Miller …
Harnessing Plant Flavonoids to Fight Pancreatic Cancer
C Niu, J Zhang, PI Okolo - Current Nutrition Reports, 2024 - Springer
This review provides strong evidence that plant flavonoids have potential against pancreatic
carcinogenesis in experimental animals through various pharmacological mechanisms …
carcinogenesis in experimental animals through various pharmacological mechanisms …
Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness
Aims Pancreatic ductal adenocarcinoma (PDAC) is often intrinsically-resistant to standard-of-
care chemotherapies such as gemcitabine. Acquired gemcitabine resistance (GemR) can …
care chemotherapies such as gemcitabine. Acquired gemcitabine resistance (GemR) can …
Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single‐agent fibroblast growth factor receptor‐specific inhibitors in pancreatic …
Q Lin, A Serratore, J Perri… - British Journal of …, 2024 - Wiley Online Library
Abstract Background and Purpose Elevated fibroblast growth factor receptor (FGFR) activity
correlates with pancreatic adenocarcinoma (PDAC) progression and poor prognosis …
correlates with pancreatic adenocarcinoma (PDAC) progression and poor prognosis …